Metformin associated lactic acidosis following administration of intravenous contrast media
Jackson N
Record ID 32003000708
English
Authors' objectives:
This aim of this report was to assess the risk associated with contrast agents and patients on Metformin.
Authors' recommendations:
- Findings from a systematic review and a case series have shown that Metformin related lactic acidosis occurs mainly in patients with abnormal renal function. For this reason the authors agree that Metformin should be discontinued for 48 hours after the use of contrast media in patients with abnormal renal function, and that renal function should be reassessed before Metformin is reinstituted
- There appears to be a lack of evidence behind the requirement to withhold Metformin after the use of contrast media in patients with normal renal function
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.med.monash.edu.au/healthservices/cce/evidence/
Year Published:
2002
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Australia
MeSH Terms
- Acidosis, Lactic
- Kidney Diseases
- Contrast Media
Contact
Organisation Name:
Centre for Clinical Effectiveness
Contact Address:
Monash Institute of Health Services Research, Block E, Monash Medical Centre, Locked Bag 29, Clayton, Victoria 3168, Australia. Tel: +61 3 9594 7505; Fax: +61 3 9594 7552.
Contact Name:
cce@med.monash.edu.au.
Contact Email:
cce@med.monash.edu.au.
Copyright:
Centre for Clinical Effectiveness (CCE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.